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To the Editor,
We thank Dr Yu for his comments in response to our 
article. According to Dr Yu, we did not sufficiently address 
2 misconceptions on perioperative management in pa-
tients with a pheochromocytoma. He states that we sug-
gested that control of hypertension is more important 
than prevention of cardiovascular complications, based 
on the order in which we mentioned these goals. These 
goals, however, were described in random order and we 
did not mean to imply that one was more important than 
the other. Fluctuations in blood pressure and heart rate are 
nevertheless common in pheochromocytoma, may have 
deleterious effects per se, and are amenable to medical 
management. We do agree with Dr Yu that normotension 
does not preclude the occurrence of cardiovascular com-
plications, an important message to which we have also 
brought attention.
In response to the alleged second misconception in our 
paper, Dr Yu suggests that the perioperative management 
should be more individualized. We agree that in general, 
any treatment should be tailored to the patient. In fact, 
when aiming at predefined perioperative hemodynamic tar-
gets as we suggest, this automatically translates into an in-
dividualized approach to the selection of drugs and doses. 
Unfortunately, however, it is still largely unknown which 
specific preoperative factors reliably predict a person’s 
perioperative risk and the ensuing optimal treatment. His 
statement that preoperative echocardiography and 24-hour 
ambulatory blood pressure monitoring is unnecessary in 
patients harboring a small pheochromocytoma (ie, < 3 cm) 
who are physically fit implies that pheochromocytoma/
paraganglioma (PPGL)-related cardiovascular complica-
tions are negligible under these circumstances. The notion 
of skipping these routine and noninvasive investigations is, 
however, not corroborated by the literature that was cited. 
For example, the study by Yu et al demonstrated that 17% 
of patients with a tumor smaller than 3  cm also devel-
oped severe cardiovascular complications during unrelated 
procedures (1). In addition, in the series by Chen and col-
leagues, a smaller tumor size was not accompanied with a 
lower rate of complications (2). Moreover, the clinical pic-
ture of a PPGL-induced cardiomyopathy is often atypical. 
Only a minority presents with classical cardiac symptoms, 
and absence of cardiovascular risk factors or a young age 
does not protect against the development of this form of 
cardiomyopathy (3-5). Furthermore, the assumption that 
tumor size strongly influences the risk for cardiac compli-
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also shown in the review by Shen and Yu (6). Of relevance, 
preoperative demonstration of abnormalities on electro-
cardiogram or echocardiography does predict an increased 
risk for cardiac complications (6).
In conclusion, a small PPGL size or the absence of symp-
toms does not reliably predict a low perioperative risk. 
We do agree that the controversy with respect to the clin-
ical value of presurgical treatment with α-adrenoreceptor 
blockers in modern-day medicine could be resolved only 
by a well-designed placebo-controlled trial. Until then, we 
recommend following the Endocrine Society’s guideline 
that all patients with a PPGL, regardless of blood pres-
sure and tumor size, should undergo preoperative evalu-
ation of cardiac function and blood pressure and receive 
presurgical treatment with α-adrenoreceptor blockers (7).
Additional Information
Correspondence and Reprint Requests: Henri J.L.M. Timmers, 
MD, PhD, Radboud University Medical Center Nijmegen, De-
partment of Internal Medicine, Section of Endocrinology, Geert 
Grooteplein Zuid 10, 6525 GA Nijmegen, P.O. Box 9101, 6500 HB, 
the Netherlands. E-mail: Henri.Timmers@radboudumc.nl.
Disclosure Summary: The authors have nothing to disclose.
References
 1. Yu  R, Pitts  A, Wei  M. Small pheochromocytomas: signifi-
cance, diagnosis, and outcome. J Clin Hypertens (Greenwich). 
2012;14(5):307-315.
 2. Chen Y, Chomsky-Higgins K, Nwaogu I, et al. Trends in adrenal 
surgery—the changing nature of tumors and patients. J Surg 
Res. 2019;236:129-133.
 3. Yu R, Nissen NN, Bannykh SI. Cardiac complications as initial 
manifestation of pheochromocytoma: frequency, outcome, and 
predictors. Endocr Pract. 2012;18(4):483-492.
 4. Zhang R, Gupta D, Albert SG. Pheochromocytoma as a revers-
ible cause of cardiomyopathy: analysis and review of the litera-
ture. Int J Cardiol. 2017;249:319-323.
 5. Y-Hassan  S, Falhammar  H. Pheochromocytoma- and 
paraganglioma-triggered Takotsubo syndrome. Endocrine. 
2019;65(3):483-493.
 6. Shen J, Yu R. Perioperative management of pheochromocytoma: 
the heart of the issue. Minerva Endocrinol. 2013;38(1):77-93.
 7. Lenders  JW, Duh  QY, Eisenhofer  G, et  al; Endocrine Society. 
Pheochromocytoma and paraganglioma: an Endocrine 











roningen user on 16 D
ecem
ber 2020
